<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11862554</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.492</article-id><article-id pub-id-type="other">EPP0315</article-id><article-id pub-id-type="pii">S0924933824004929</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Clozapine to treat aggression and agitation in advanced dementia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Michael</surname><given-names>A. E.</given-names></name><xref rid="aff1090" ref-type="aff">
<sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Michael</surname><given-names>N.</given-names></name><xref rid="aff1091" ref-type="aff">
<sup>2</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Erfurth</surname><given-names>A.</given-names></name><xref rid="aff1092" ref-type="aff">
<sup>3</sup></xref><xref rid="cor0353" ref-type="corresp">
<sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kujovic</surname><given-names>M.</given-names></name><xref rid="aff1093" ref-type="aff">
<sup>4</sup></xref></contrib></contrib-group><aff id="aff1090">
<sup>1</sup><institution>Johannes Wesling Klinikum Minden</institution>, <city>Minden</city>
</aff><aff id="aff1091">
<sup>2</sup><institution>Krankenhaus Elbroich</institution>, <city>D&#x000fc;sseldorf</city>, <country>Germany</country>
</aff><aff id="aff1092">
<sup>3</sup>1st Department of Psychiatry and Psychotherapeutic Medicine, <institution>Klinik Hietzing</institution>, <city>Vienna</city>, <country>Austria</country>
</aff><aff id="aff1093">
<sup>4</sup><institution>LVR-Klinikum
</institution>, <city>D&#x000fc;sseldorf</city>, <country>Germany</country>
</aff><author-notes><corresp id="cor0353">
<label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="467">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S231</fpage><lpage>S232</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824004929a.pdf"/><abstract><sec id="sec2119"><title>Introduction</title><p>Agitation and aggression are a serious problem in clinical psychiatry, especially in multimorbid patients of advanced age, including those with dementia.</p></sec><sec id="sec2120"><title>Objectives</title><p>We wanted to investigate to what extent clozapine could be an option in the treatment of selected refractory patients.</p></sec><sec id="sec2121"><title>Methods</title><p>A retrospective study included patients with a diagnosis of dementia who were treated with clozapine in a specialist geriatric psychiatry unit between August 2018 and February 2022, and medical records were systematically reviewed. The Clinical Global Impressions Scale was used for the assessment of improvement and the Pittsburgh Agitation Scale for the assessment of symptom reduction. In addition, there was detailed documentation of side effects and clinical features.</p></sec><sec id="sec2122"><title>Results</title><p>
A total of 31 patients with a median age of 82 years were identified.</p></sec><sec id="sec2123"><title>Conclusions</title><p>
In conclusion, clozapine was effective and well tolerated in 23 patients. This suggests that low-dose clozapine may help alleviate the suffering of difficult-to-treat multimorbid patients with advanced dementia and their carers. However, adverse effects, particularly in patients with cardiovascular and pulmonary impairment, should be carefully monitored.</p></sec><sec id="sec2124"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>